Trissil

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Trissil

Quick Facts

Property Description
Active ingredient Levofloxacin
Form Film-Coated Tablet, Oral Solution, Injection, Ophthalmic Solution
Pharmacological class Fluoroquinolone Antibiotic
Common use Systemic and local elimination of bacterial infections
Origin Synthetic Antibacterial Molecule

What Type of Medicine is Trissil (Levofloxacin)?

Trissil is a prescription medicinal preparation containing the core active ingredient Levofloxacin, which is a synthetic antibacterial molecule recognized as a highly effective Fluoroquinolone Antibiotic. This agent functions as a broad-spectrum antibiotic, a property that is clinically recognized for its ability to target a wide variety of bacterial pathogens. The general objective is to achieve a decisive bactericidal effect for clearing systemic or local bacterial infections.

Understanding the Composition and Available Forms

The core therapeutic component is the Single Active Ingredient Levofloxacin, supplied as its Hemihydrate. Chemically, Levofloxacin is distinct because it is the purified, highly active S-isomer of the older compound Ofloxacin. This specific isomer formulation is a defining feature of the preparation, focusing its antibacterial efficacy. The medicine is available in several pharmaceutical preparations, including the Film-Coated Tablet for systemic Oral Use, as well as specialized forms for Intravenous administration (Injection) and local application, such as the Ophthalmic Solution.

General Purpose: What Does Trissil Help Achieve?

The general purpose of Trissil is to achieve a bactericidal effect by eliminating the microbial source of illness. Levofloxacin is designed to stop the fundamental life processes of bacteria by inhibiting critical enzymes, specifically DNA Gyrase and Topoisomerase IV, that are required for bacterial genetic material (DNA synthesis) to replicate. This mechanism prevents the bacteria from reproducing or repairing their DNA, resulting in the elimination of the infectious agent and serving as a standard treatment approach for common bacterial infections.

What side effects are possible with Trissil?

Possible side effects and safety information

The official regulatory safety profile for Trissil (Levofloxacin) classifies potential adverse reactions based on their frequency and the body system affected, strictly documenting the range of risks from common effects to rare, serious adverse events.

Adverse reactions are formally categorized. Common effects, reported in clinical trials, include gastrointestinal disturbances like nausea and diarrhea, as well as nervous system effects such as headache and insomnia. Other effects are documented as Uncommon or Rare, providing a graded view of incidence.

Serious Adverse Reactions

The official labeling highlights the risk of disabling and potentially irreversible serious adverse reactions affecting multiple body systems. These include Tendon Rupture (often involving the Achilles tendon), potentially long-lasting Peripheral Neuropathy, and severe central nervous system effects such as convulsions and psychosis. Other serious, label-documented risks are Aortic Aneurysm and Dissection and certain severe hypersensitivity reactions.

Safety Considerations for Special Populations

Safety risks are officially noted to be elevated in certain patient groups. Older Adults (generally over 60 years) have an increased risk of tendinopathy and aortic events. Patients with Renal Impairment may experience a higher incidence of systemic adverse reactions due to reduced clearance. The risk of blood glucose disturbances (hypoglycemia and hyperglycemia) is a specific consideration for Diabetic Patients.

Time-Related Risk Patterns

Regulatory documents state that certain serious reactions are not limited to the treatment period. Tendon disorders may occur as early as within 48 hours of treatment initiation or can be reported up to several months after discontinuation of the medicine.

Overdose and Emergency Response

Overdose Manifestations and Severe Outcomes

An overdose of Trissil (Levofloxacin) is documented in official regulatory sources as potentially causing central nervous system effects, known as supra-therapeutic manifestations. These presentations include confusion, dizziness, impairment of consciousness, and convulsive seizures. Gastrointestinal signs may also be present, such as nausea and mucosal erosions.

A critical and potentially life-threatening outcome that may occur is an increase in the QT interval on an electrocardiogram (ECG), which indicates a serious cardiac risk.

Required Emergency Actions and Monitoring

In the event of an overdose, immediate professional medical attention is required. The patient must be subject to careful observation and symptomatic treatment must be implemented promptly. Due to the cardiac risk, ECG monitoring is essential.

For initial management, gastric lavage should be considered shortly after ingestion to reduce systemic absorption. Antacids may also be administered to protect against documented mucosal erosions in the gastrointestinal tract.

Antidote and Treatment Limitations

Official labeling confirms that no specific antidote is known for Levofloxacin overdose. Furthermore, regulatory documents state that standard procedures such as hemodialysis, peritoneal dialysis, and Continuous Ambulatory Peritoneal Dialysis (CAPD) are not effective for the removal of the drug from the body.

Therapeutic Uses of Trissil

What Trissil Treats: Main Uses and Benefits

The medicine is relevant for managing conditions that involve susceptible bacterial infections. It is used across conditions presenting with acute episodes, including certain difficult presentations of Community-Acquired Pneumonia, Acute Pyelonephritis (kidney infection), Complicated Urinary Tract Infections, and infections of the skin like Cellulitis. It is applied across domains where additional symptomatic support is needed due to microbial invasion.

“The medication assists with maintaining functional stability by providing supportive relief when symptoms interfere with routine activities.”

When symptoms related to systemic imbalance, such as fever, or symptoms related to physical discomfort, such as painful urination or difficulty breathing, become more disruptive during flare-ups, this medicine is commonly used. Its application often occurs during phases when symptoms become more noticeable, providing support that helps ease the overall symptom burden and promotes improved comfort during these periods of heightened symptoms. This therapeutic approach is also relevant for addressing specialized systemic illnesses like Anthrax and Plague in specific exposure cohorts.


Quick Fact: Relief for Acute Infection Symptoms

Symptom Domain Conditions Addressed Primary Benefit to Patient
Systemic/Respiratory Pneumonia, Acute Bronchitis flare-ups Assists with maintaining functional stability
Genitourinary Kidney/Complicated UTI, Prostatitis Contributes to improved comfort during episodes
Localized Tissue Cellulitis, Acute Rhinosinusitis Provides supportive relief for inflammation/pain

Regulatory References

  1. DailyMed (NIH/FDA) labeling for Levofloxacin

Eligibility and Restrictions for Use

Eligibility Map: Who can and cannot use Trissil — Official Regulatory Information

The eligibility profile for Trissil (Levofloxacin) is defined by strict regulatory guidelines from authorities like the FDA and EMA. Use is categorized by contraindications, restrictions, and conditional allowance.

Populations for Whom Use is Contraindicated

  • Patients with hypersensitivity to Levofloxacin or any other quinolone.
  • Individuals with epilepsy or a history of tendon disorders related to prior fluoroquinolone use.
  • Pregnant women and breastfeeding women (Contraindicated, SmPC/EMA).
  • Children or growing adolescents (generally under 18 years of age), as use is typically contraindicated in this population

.

Conditional and Restricted Use

  • Uncomplicated Infections: Use for uncomplicated infections (e.g., uUTI, acute sinusitis) must be reserved only for patients who have no alternative treatment options (FDA mandate).
  • Organ Function: Patients with impaired renal function (Creatinine clearance leq 50 mL/min) are eligible, provided a mandatory dose adjustment is performed.
  • Comorbidity: The medicine should be avoided in patients with a known history of myasthenia gravis.
  • Infants: Safety and effectiveness have not been established in children under 6 months of age.

What should I know about interactions with other medicines?

Official Interaction Patterns

The interaction profile for Trissil (Levofloxacin) is defined by pharmacokinetic and pharmacodynamic relationships with co-administered substances, as documented in regulatory sources.

Prohibited Combinations and Timing Constraints Co-administration with medicines that prolong the QT interval, such as Class IA and Class III antiarrhythmics, is formally contraindicated due to the risk of additive cardiac effects. The oral absorption of Trissil is significantly decreased by multivalent cation-containing products (e.g., antacids, sucralfate, iron or zinc supplements). To prevent this reduction in exposure, administration must be separated by at least 2 hours before or 6 hours after the cation-containing product. Probenecid and Cimetidine reduce Levofloxacin’s renal clearance, resulting in increased systemic levels.

Pharmacodynamic Risk Reinforcement Interactions that increase specific risks are documented for several drug classes. Co-administration with Corticosteroids increases the risk of tendinitis and tendon rupture. The use of Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) is noted to increase the risk of CNS stimulation. Antidiabetic agents (e.g., Insulin) may result in disturbances of blood glucose control. Furthermore, the effect of Warfarin is officially enhanced, requiring mandatory monitoring of Prothrombin Time (INR). These interaction risks are documented to be of higher clinical significance for geriatric patients and individuals with renal impairment.

Mechanism of Action

Trissil functions as a dual type II bacterial topoisomerase inhibitor, selectively accumulating at the cellular level within susceptible bacterial organisms. Its primary biological targets are DNA gyrase (a GyrA2 GyrB2 heterotetramer) and DNA topoisomerase IV (a ParC2 ParE2 heterotetramer).

The agent interacts with these enzymes as a non-competitive inhibitor by binding to the enzyme-DNA complex near the active site tyrosine residues. This interaction stabilizes the covalent enzyme-DNA cleavage complex intermediate, specifically blocking the enzyme's ability to religate the double-strand DNA break.

This molecular interaction prevents the enzymes from executing their catalytic function of regulating DNA supercoiling and segregating daughter chromosomes. The resulting stabilization of the cleaved DNA-enzyme complex blocks the movement of the DNA replication fork and transcription complexes, leading to a cascade of DNA damage and an accumulation of irreparable double-strand DNA breaks within the bacterial genome. This perturbation of DNA integrity represents the core intracellular consequence.

The ultimate system-level physiological consequence is the inhibition of bacterial cellular division and subsequent cessation of microbial proliferation.

Dosage and Administration Information

Trissil (Levofloxacin) is administered either orally (as film-coated tablets or oral solution) or intravenously as an infusion for systemic treatment. The standard adult dosing regimen is once daily (every 24 hours), with doses typically ranging from 250 mg to the maximum of 750 mg, depending on the specific infection being managed.

The total duration of the treatment course is infection-specific, varying from short courses of 3 to 5 days to longer courses lasting up to 60 days. The systemic dose is the same regardless of the initial route (IV or oral) due to the bioequivalence of the formulations.

For oral intake, the tablets may generally be taken without regard to meals. However, the oral solution is recommended to be taken one hour before or two hours after food. A critical administration constraint for all oral forms is the requirement to separate intake from medications containing polyvalent cations, such as iron, zinc, or magnesium/aluminum-based antacids, by at least two hours to prevent reduced absorption.

Intravenous administration requires the solution to be delivered by slow infusion, typically over 60 minutes for the 500 mg dose, or 90 minutes for the 750 mg dose. Dose adjustment is mandatory for patients with impaired renal function (creatinine clearance < 50 mL/min), often involving a dose reduction or an extension of the dosing interval to every 48 hours.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Trissil (Levofloxacin)


Evidence for Use in Respiratory Tract Infections: Pneumonia and Bronchitis

Research exploring the use of this agent in bacterial respiratory illnesses primarily involves Randomized Controlled Trials (RCTs). These studies were conducted alongside other established treatments and were used to evaluate different treatment durations, such as short-course versus longer-course regimens. Research examined outcomes related to systemic or functional imbalance, specifically monitoring for the measured resolution of clinical symptoms like fever, cough, and other outcomes describing episodic or acute changes associated with pneumonia. Findings describe patterns observed in the studies where clinical outcomes were measured during the defined treatment interval. Limitations include that research findings relate specifically to the populations studied. Data for certain groups, such as those with highly complex or specific immunosuppressive co-morbidities, remain insufficient.


Evidence for Use in Kidney and Complicated Urinary Tract Infections

This agent was studied in the context of severe infections of the urinary tract, including Acute Pyelonephritis (kidney infection) and Complicated Urinary Tract Infections (cUTI). The research included RCTs designed to determine if measured outcomes were similar to those achieved with standard treatments. Studies monitored for two primary types of outcomes: Clinical Success (measured resolution of acute symptoms like painful urination and fever) and Microbiologic Eradication (measured clearing of the infectious bacteria from the urine). Research settings often adhere to guidelines that reserve studies on this agent for cases where no alternative treatment options exist. This means that data for its use where alternative treatment options are available are limited.


Key Uncertainties and Research Gaps

For highly specialized systemic illnesses like Inhalational Anthrax and Plague, the evidence structure involves specific research protocols. Regulatory evidence structure is derived from Animal Efficacy Studies combined with Pharmacokinetic/Pharmacodynamic (PK/PD) modeling, as direct human efficacy trials are not feasible. A significant gap is the lack of direct human efficacy data for these rare diseases, as this relies on the extrapolation of animal data. Furthermore, the long-term effects are not fully established for extended treatment durations in special populations, and continuous research is ongoing to address the need for updated information regarding antibiotic resistance patterns.

Key Studies & References

  1. A randomized, open, multicenter clinical study on the short course of intravenous infusion of 750 mg of levofloxacin and the sequential standard course of intravenous infusion/oral administration of 500 mg of levofloxacin for treatment of community-acquired pneumonia
  2. Respiratory fluoroquinolones for the treatment of community-acquired pneumonia: a meta-analysis of randomized controlled trials

Frequently Asked Questions (FAQ)

Common questions about Trissil (FAQ)

Q: How is Trissil different from other similar treatments I've heard about?

A: According to the official product information, the active ingredient in Trissil is Levofloxacin, which is chemically defined as the purified S-isomer of an older medicine called Ofloxacin. This specific S-isomer formulation is a key distinction in the medicine's preparation, focusing its antibacterial efficacy.

Q: Can Trissil cause long-term side effects?

A: Regulatory documents describe a risk of serious adverse reactions that may be disabling and potentially irreversible, meaning they may persist. These include conditions like peripheral neuropathy (nerve damage) and tendon problems. In some cases, official reports indicate that tendon issues may occur up to several months after stopping the medicine.

Q: Does Trissil interact with common pain relievers like ibuprofen?

A: Official interaction patterns indicate there is an increased risk of Central Nervous System (CNS) stimulation when Trissil is taken alongside medicines belonging to the Non-Steroidal Anti-Inflammatory Drug (NSAID) class. This caution is extended to commonly used pain relievers that belong to the NSAID class.

Q: Is it necessary to avoid any specific foods or drinks while taking Trissil?

A: Regulatory documents require that Trissil be separated from any products containing multivalent cations, such as iron or zinc supplements and magnesium/aluminum-based antacids. While the oral tablets may generally be taken without regard to meals, the oral solution has a specific condition: it is typically recommended to be taken one hour before or two hours after food.

Q: Can older adults typically use Trissil?

A: Official information indicates that individuals 60 years of age and older have a documented elevated risk for certain serious adverse reactions. These include risks related to tendons (tendinopathy) and documented cardiac events.

Q: Why is Trissil often taken at a certain time of day?

A: According to the official drug information, the medicine is typically prescribed for administration once daily (every 24 hours). This regimen is consistent with the drug’s long half-life, supporting the standard once-daily administration.

Q: Is it normal to feel a little dizzy when first starting Trissil?

A: Yes, dizziness is documented in the reports from clinical trials as one of the commonly reported side effects. Other common effects include gastrointestinal issues and insomnia.

Q: How does Trissil fit into a full treatment plan?

A: Regulatory guidelines describe how the medicine is positioned for use in certain infections. Specifically, for certain uncomplicated infections (such as some urinary tract infections), the use of this medicine must be reserved for patients who have no alternative treatment options.

Q: What is the purpose of the different strengths or forms of Trissil?

A: The active ingredient is supplied in several different forms, including film-coated tablets, oral solutions, and intravenous injections. These different forms allow the medicine to be used to suit various types of infection and required routes of treatment. Different strengths are used based on the specific infection being treated.

Q: Does Trissil interact with vitamins or herbal supplements?

A: Official information states that the medicine's oral absorption is significantly decreased when taken with multivalent cation-containing products, which includes certain supplements. Specifically, supplements containing iron and zinc must be separated from Trissil by at least two hours, as official documents indicate these products can significantly reduce the medicine’s absorption.

Q: What is the shelf life of Trissil, and how should it be kept?

A: Regulatory documents strictly define the storage conditions required to maintain the medicine's stability, which includes keeping it protected from light, moisture, and freezing temperatures. The maximum shelf life for the tablets is commonly assigned up to 36 months, provided the strict storage conditions are maintained as specified in regulatory documents.

Q: Why do doctors switch patients from one medicine to Trissil?

A: Regulatory guidance reserves the use of this medicine for certain cases where alternative treatments are not an option. Official research also continuously addresses the need for updated information regarding patterns of antibiotic resistance, which can be a factor in choosing a course of treatment.

Q: What kind of studies were done before Trissil was approved?

A: The evidence supporting the use of Trissil is derived from various sources. For common infections, this includes Randomized Controlled Trials (RCTs). For rare diseases like anthrax, the evidence structure relies on Animal Efficacy Studies combined with Pharmacokinetic/Pharmacodynamic (PK/PD) modeling.

Q: Can I take Trissil if I have a history of heart issues?

A: Regulatory documents note increased risks for patients with certain heart conditions, such as a known history of prolonged QT interval or uncorrected low potassium. The official label also documents a risk of Aortic Aneurysm and Dissection.

Q: Are there any special instructions for traveling with Trissil?

A: Official storage instructions require the medicine to be kept in its original container and protected from light, freezing, and excessive heat. Maintaining these conditions while traveling is important to ensure product stability.

Q: Do any official documents describe why Trissil might not work for some people?

A: Official research identifies that continuous studies are needed to address updated information regarding patterns of antibiotic resistance, which can prevent the medicine from working effectively. Additionally, patient counseling notes that failure to take the full course of treatment may reduce its immediate and future effectiveness.

Q: How long does it usually take for Trissil to start working?

A: Official pharmacokinetic information indicates the active ingredient is rapidly absorbed following oral administration, reaching its maximum concentration in the blood in about 1.5 hours. Steady state, which represents consistent drug levels, is generally attained within 48 hours of starting the medicine.

Q: What should I do if I feel like Trissil isn't working for me?

A: Patient counseling information emphasizes that the full course of therapy must be taken exactly as directed, even if you feel better. If the symptoms of your infection do not get better, official documents state that patients should inform their physician.

Q: Are there any major safety warnings or black boxes associated with Trissil?

A: Yes, the official FDA labeling includes a Boxed Warning that highlights the risk of disabling and potentially irreversible serious adverse reactions. These warnings specifically address risks such as tendinitis, tendon rupture, peripheral neuropathy (nerve damage), and severe central nervous system effects.

Q: What happens if I stop taking Trissil suddenly?

A: Official patient counseling states that skipping doses or not completing the full course may decrease effectiveness and may increase the likelihood of bacterial resistance. The medication should be taken exactly as directed and should not be stopped.

Q: Does Trissil affect my ability to drive or operate machinery?

A: The FDA-approved patient medication guide advises that Trissil can cause effects such as dizziness and lightheadedness. The official medication guide advises patients to know how the medicine affects them before driving or operating machinery.

Q: Are there any known issues with taking Trissil and birth control pills?

A: Official information notes that antibiotics in this class may potentially reduce the effect of hormonal contraceptives that contain ethinyl estradiol. Additionally, the absorption-reducing interaction with iron-containing products means that birth control pills containing iron must be separated from Trissil by several hours.

Q: Is Trissil addictive or habit-forming?

A: The official safety profile focuses on serious adverse reactions involving body systems like the central nervous system and tendons. The official labeling does not list abuse, addiction, or dependence as known risks associated with the medicine.

Q: Do I need to get regular blood tests while taking Trissil?

A: Regulatory documents mandate that patients taking the blood thinner Warfarin must undergo monitoring of their Prothrombin Time (INR). Also, patients taking antidiabetic agents must monitor their blood glucose levels carefully, as the medicine may cause disturbances in glucose control.

Q: Can Trissil affect my blood pressure?

A: Official information advises that rapid intravenous administration should be avoided due to a documented risk of hypotension (low blood pressure). Low blood pressure is also noted as a sign of a rare, severe allergic reaction.

Q: What are the possible risks of combining Trissil with alcohol?

A: Official safety information indicates that combining Trissil with alcohol may increase the risk of certain side effects. These effects include dizziness and mental confusion.

Q: Can Trissil be split in half if the tablet has a score line?

A: Official documents note that the film-coated tablets can be divided at the score line to adapt the dose, where necessary. However, the tablets should be swallowed whole without crushing.

Q: Does Trissil cause weight gain or weight loss?

A: General weight changes are not listed as common side effects of Trissil. However, official patient information notes that a significant weight gain can be a sign of kidney problems, which is a documented serious risk.

Q: What if I experience a rare or unexpected side effect with Trissil?

A: Patient counseling information instructs that the medicine should be immediately discontinued if any severe or unexpected signs occur, such as a severe allergic reaction or tendon pain. In such events, prompt contact with a healthcare provider is advised.

Q: Is there a generic version of Trissil available?

A: The official documentation identifies the active ingredient in Trissil as Levofloxacin. Levofloxacin is the non-proprietary or generic name for the drug substance.

Q: Does Trissil interact with caffeine?

A: Studies involving drugs in the same class as Trissil's active ingredient have indicated that they can cause caffeine to persist for a longer time in the bloodstream. This may potentially result in an intensified effect of caffeine.

Q: Can Trissil affect my liver function?

A: Regulatory documents state that signs of hepatotoxicity (liver injury) require prompt medical review and discontinuation of the medicine. Regulatory information documents a risk of hepatotoxicity (liver damage), which has been severe in some cases.

Q: Is it true that Trissil can cause changes in vision?

A: Official adverse event reporting has documented changes in vision, including blurry vision and optic neuritis, as rare but possible serious adverse reactions.

How should Trissil be stored and disposed of?

How to Store and Dispose of Trissil (Levofloxacin)

The storage and disposal of Trissil (Levofloxacin) are strictly defined by regulatory labeling to ensure product stability and safety. The medicine must be kept out of the reach of children and stored in its tightly closed, original container.

Official Storage Requirements

Product Form Temperature Range Environmental Protection
Oral Forms (Tablet, Solution) Controlled Room Temperature (20 C to 25 C) Protect from light, moisture, excessive heat, and do not freeze.
Injection (IV Solution) CRT (20 C to 25 C) or Refrigerated (2 C to 8 C) Must be kept from freezing and protected from light.

Disposal

Unused or expired Levofloxacin must be safely discarded following government guidelines for drug disposal. This often involves using a drug take-back program or mixing the medication with an undesirable substance before placing it in the household trash.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Trissil found in:

A-Z Index: